We analyzed two assertions about GLP-1 receptor agonist therapy and muscle loss in adults with MASLD, and both point in the same direction. What we’ve found so far suggests that muscle strength is not reduced during treatment, even when people lose a lot of weight. This is based on measurements like handgrip strength and how easily someone can stand up from a chair, which are common ways to check muscle function [1]. We also found that when weight is lost, most of it comes from fat or fluid, not from lean muscle tissue. In most studies, muscle mass made up less than 30% of the total weight lost [2]. This doesn’t mean muscle is completely untouched — weight loss can sometimes affect lean tissue — but the evidence we’ve reviewed shows that when GLP-1 agonists are used in people with MASLD, the body seems to preserve muscle better than expected. The changes in strength and body composition suggest the therapy isn’t pulling muscle apart as a primary source of energy. Still, we’re only looking at two assertions, and both are based on a limited number of studies. We don’t know how this plays out over many years, or in people with very advanced disease. For someone considering this therapy, the current evidence doesn’t raise a red flag about losing muscle strength or mass. If you’re worried about staying strong while losing weight, these findings offer some reassurance — but ongoing monitoring and resistance training remain important, as they are with any weight-loss approach.